Its role Owner
PharmaEssentia Corporation is a Taiwan-based biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of novel biologic therapies. Primarily focused on hematology and oncology, the company has developed expertise in pegylated interferon technology, with its lead product being a modified form of interferon alfa-2b used to treat myeloproliferative disorders such as polycythemia vera.
Headquartered in Taipei, the company maintains international operations, including ownership of a biologics manufacturing plant in Toa Baja, Puerto Rico. This facility supports the production of its pharmaceutical products and facilitates compliance with regulatory requirements in key markets like the United States and Europe.
PharmaEssentia participates in the broader pharmaceutical and chemical industry through its involvement in biologics production. As a publicly traded entity, it operates independently without affiliation to a larger corporate group. Its position in the industry is that of an innovative player specializing in rare disease treatments, leveraging Taiwan's strong biotechnology ecosystem for research while expanding manufacturing capabilities abroad.
The company's activities include clinical development, regulatory submissions, and market expansion for its pipeline of therapies. This strategic approach allows PharmaEssentia to address unmet medical needs in oncology and immunology while building a sustainable business model in the competitive biopharma sector.
Also known as PharmaEssentia Corp..
chemXplore tracks 1 project involving PharmaEssentia, of which one is active.
active all projects
